Department of Public and Child Dental Health, Dublin Dental University Hospital, University of Dublin, Trinity College, Dublin, Ireland; Department of Paediatric Dentistry, School of Dentistry, University of São Paulo, São Paulo, Brazil.
Department of Paediatric Dentistry, School of Dentistry, University of São Paulo, São Paulo, Brazil.
J Dent. 2020 Oct;101:103446. doi: 10.1016/j.jdent.2020.103446. Epub 2020 Aug 3.
To evaluate the 2-year survival rate and the cost-effectiveness of Atraumatic Restorative Treatment (ART) using three different glass ionomer cements (GICs) for restoring occlusal dentin caries lesions in primary molars.
One hundred and fifty (150) 4-8-year-old children were selected, randomly allocated and treated in school tables according to the restorative material: Fuji IX Gold Label (GC Corp), Vitro Molar (nova DFL) and Maxxion R (FGM), the latter two being low-cost brands. Materials and professionals' costs were considered to analyse baseline total cost, and from this the cumulative cost of each treatment was calculated. Restoration assessments were performed after 2, 6, 12 and 24 months by an independent calibrated examiner. Restoration survival was estimated using Kaplan-Meier survival analysis and Cox regression was used to test association with clinical factors. Bootstrap regression (1,000 replications) compared material´s cost over time and Monte-Carlo simulation was used to build cost-effectiveness scatter plots.
The overall survival rate of occlusal ART restorations after 2 years was 53% (Fuji IX = 72.7%; Vitro Molar = 46.5%; Maxxion R = 39.6%). Restorations performed with Vitro Molar and Maxxion R were more likely to fail when compared to Fuji IX. At baseline, Fuji IX was the more expensive option (p < 0.001), however, considering the simulation of accumulated cost caused by failures until 2-year evaluation, no difference was found between the groups.
After 2 years' follow up, restorations performed with Fuji IX proved to be superior in terms of survival, with a similar overall cost, when compared to low-cost glass ionomers cements (Vitro Molar and Maxxion R).
评估使用三种不同玻璃离子水门汀(GIC)对乳磨牙窝沟龋损进行非创伤性修复治疗(ART)的 2 年生存率和成本效益。
选择了 150 名 4-8 岁的儿童,按照修复材料在学校桌子上进行随机分组和治疗:富士 IX 金标(GC 公司)、Vitro Molar(nova DFL)和 Maxxion R(FGM),后两者是低成本品牌。考虑材料和专业人员的成本来分析基线总成本,并从该总成本中计算出每种治疗方法的累积成本。使用独立校准的检验员在 2、6、12 和 24 个月时进行修复评估。使用 Kaplan-Meier 生存分析估计修复体的生存率,并使用 Cox 回归检验与临床因素的相关性。使用 bootstrap 回归(1000 次复制)比较材料的随时间变化的成本,使用蒙特卡罗模拟构建成本效益散点图。
2 年后,窝沟 ART 修复体的总体生存率为 53%(富士 IX=72.7%;Vitro Molar=46.5%;Maxxion R=39.6%)。与富士 IX 相比,使用 Vitro Molar 和 Maxxion R 进行修复的更容易失败。在基线时,富士 IX 是更昂贵的选择(p<0.001),但是,考虑到直到 2 年评估时失败造成的累积成本模拟,各组之间没有差异。
在 2 年的随访后,与低成本玻璃离子水门汀(Vitro Molar 和 Maxxion R)相比,使用富士 IX 进行修复在生存率方面表现更好,总成本相似。